The beneficial effect of n-3 polyunsaturated fatty acids on doxorubicin-induced chronic heart failure in rats

Journal of International Medical Research

Volumn 38, Issue 3, 2010, Pages 940-948

  Teng, Ll ^a   Shao, L ^a   Zhao, Yt ^a   Yu, X ^a   Zhang, Df ^a   Zhang, H ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Doxorubicin; Heart failure; N 3 fatty acids; Rat model

Indexed keywords

DOXORUBICIN; INTERLEUKIN 10; OMEGA 3 FATTY ACID; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; HEART FUNCTION; HISTOPATHOLOGY; MALE; MICROSCOPY; NONHUMAN; RAT; ANIMAL; BLOOD; CHRONIC DISEASE; DISEASE MODEL; DRUG EFFECTS; HEART; HEART MUSCLE; HEART VENTRICLE FUNCTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TOXICITY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DOXORUBICIN; ECHOCARDIOGRAPHY; FATTY ACIDS, OMEGA-3; HEART; HEART FAILURE; INTERLEUKIN-10; MALE; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION;

EID: 77954768061     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800320     Document Type: Article

References (38)

1. Hunt SA, Abraham WT, Chin MH, et al: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: el-e82.
2. Swedberg K, Cleland J, Dargie H, et al: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: lll5-1140.
3. Schocken DD, Benjamin EJ, Fonarow GC, et al: Prevention of heart failure. Circulation 2008; 117: 2544-2565.
4. Weber P, Raederstorff D: Triglyceride-lowering effect of omega-3 LC polyunsaturated fatty acids - a review. Nutr Metab Cardiovasc Dis 2000; 1: 28-37.
5. Leaf A, Kang JX, Xiao YF, et al: Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 2003; 107: 2646-2652.
6. von Schacky C, Harris WS: Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res 2007; 73: 310-315.
7. Lichtenstein AH, Appel LJ, Brands M, et al for the American Heart Association Nutrition Committee: Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006; 114: 82-96.
8. Mozaffarian D, Bryson CL, Lemaitre RN, et al: Fish intake and risk of incident heart failure. J Am Coll Cardiol 2005; 45: 2015-2021.
9. Duda MK, O'Shea KM, Tintinu A, et al: Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res 2009; 81: 319-327.
10. Harris WS: n-3 Fatty acids and serum lipoproteins: animal studies. Am J Clin Nutr 1997;65(5 suppl): 1611S-1616S.
11. Harris WS: n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997; 65(5 suppl): 1645S-1654S.
12. Geleijnse JM, Giltay EJ, Grobbee DE, et al: Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 2002; 20: 1493-1499.
13. Pepe S, Tsuchiya N, Lakatta EG, et al: PUFA and aging modulate cardiac mitochondrial membrane lipid composition and Casup2/sup+ activation of PDH. Am J Physiol 1999; 276: H149-H158.
14. McMillin JB, Bick RJ, Benedict CR: Influence of dietary fish oil on mitochondrial function and response to ischemia. Am J Physiol 1992; 263: H1479-H1485.
15. Zhao YT, Shao L, Teng LL, et al: Effects of n-3 polyunsaturated fatty acids therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure. J Int Med Res 2009; 37: 1831-1841.
16. Lanza E, Rozza A, Favalli L, et al: The rat model in the comparative evaluation of anthracyclines cardiotoxicity. Tumori 1989; 75: 533-536.
17. Yeung TK, Simmonds RH, Hopewell JW: The relative toxicity of intravenous and intraperitoneal doses of epirubicin. Cancer Chemother Pharmacol 1989; 24: 211-218.
18. Matsui H, Morishima I, Hayashi K, et al: Dietary fish oil does not prevent doxorubicin-induced cardiomyopathy in rats. Can J Cardiol 2002; 18: 279-286.
19. Schjott J, Brurok H, Jynge P, et al: Effects of eicosapentaenoic acid and docosahexaenoic acid diet supplement on tolerance to the cardiotoxicity of epirubicin and to ischaemia reperfusion in the isolated rat heart. Pharmacol Toxicol 1996; 79: 65-72.
20. Chakrabarti K, Hopewell J, Wilding D, et al: Modification of doxorubicin-induced cardiotoxicity: effect of essential fatty acids and ICRF-187 (dexrazoxane). Eur J Cancer 2001; 37: 1435-1442.
21. Hrelia S, Bordoni A, Biagi PL: Role of gamma-linolenic acid in counteracting doxorubicin-induced damage in cultured rat cardiomyocytes. Prostaglandins Leukot Essent Fatty Acids 2001; 64: 139-145.
22. Castellani S, Paladini B, Paniccia R, et al: Increased renal formation of thromboxane A2 and prostaglandin F2a in heart failure. Am Heart J 1997; 133: 94-100.
23. Zamorano B, Carmona MT: Prostaglandin-E2 and cyclic adenosine 3'-5' monophosphate levels in the hypertrophied rat heart. Biol Res 1992; 25: 85-89.
24. Newman WH, Frankis MB, Halushka PV: Increased myocardial release of prostacyclin in dogs with heart failure. J Cardiovasc Pharmacol 1983; 5: 194-201.
25. Packer M: Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation 1995; 92: 1379-1382.
26. Levine B, Kalman J, Mayer L, et al: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-241.
27. Aukrust P, Gullestad L, Ueland T, et al: Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med 2005; 37: 74-85.
28. Sharma R, Bolger AP, Li W, et al: Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Cardiol 2003; 92: 188-193.
29. Aukrust P, Yndestad A, Ueland T, et al: Antiinflammatory trials in chronic heart failure. Heart Fail Monit 2006; 5: 2-9.
30. Amosova EN, Shpak YV, Nedozhdij AV, et al: Proinflammatory cytokine levels in patients with diastolic heart failure. Kardiol Pol 2004; 61: 17-20.
31. Candia AM, Villacorta H Jr, Mesquita ET, et al: Immune-inflammatory activation in heart failure. Arq Bras Cardiol 2007; 3: 183-190, 201-208.
32. Petkova-Kirova PS, Gursoy E, Mehdi H et al: Electrical remodeling of cardiac myocytes from mice with heart failure due to the overexpression of tumor necrosis factor-a. Am J Physiol Heart Circ Physiol 2006; 290: H2098-H2107.
33. Aukrust P, Ueland T, Lien E, et al: Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83: 376-382.
34. Valen G, Yan ZQ, Hansson GK: Nuclear factor kappa-B and the heart. J Am Coll Cardiol 2001; 38: 307-314.
35. Wong SC, Fukuchi M, Melnyk P, et al: Induction of cyclooxygenase-2 and activation of nuclear factor-KB in myocardium of patients with congestive heart failure. Circulation 1998; 98: 100-103.
36. Matsumori A, Sasayama S: The role of inflammatory mediators in the failing heart: immunomodulation of cytokines in experimental models of heart failure. Heart Fail Rev 2001; 6: 129-136.
37. Zhao Y, Joshi-Barve S, Barve S, et al: Eicosapentaenoic acid prevents LPS-induced TNF-α expression by preventing NF-kB activation. J Am Coll Nutr 2004; 23: 71-78.
38. Takano H, Nagai T, Asakawa M, et al: Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-aα expression in neonatal rat cardiac myocytes. Circ Res 2000; 87: 596-602.